Thanks! Great to know this about IRIS.
Here's a Copilot summary of your post:
🧠 What Is IRIS?
- IRIS isn’t a drug—it’s an AI tool that listens to a tumor’s RNA and finds where - the genetic instructions went wrong.
- It uses machine learning to detect unusual RNA splicing patterns that could - - be used to trigger an immune response.
🔬 How Does IRIS Work?
It follows five steps:
1. Scans tumor RNA for abnormal splice variants not found in healthy tissue.
2. Predicts which fragments might be recognized by the immune system.
3. Filters for fragments that are actually visible to immune cells.
4. Manufactures those fragments synthetically.
5. Prepares them for use in DCVax, NWBO’s dendritic cell therapy.
🧬 Why It Matters
- IRIS helps program the immune system to recognize and remember cancer cells.
- It turns DCVax into a rehearsal loop, not just a one-time treatment—building long-term immunity.
👶 Pediatric Focus
- IRIS was designed for childhood cancers where traditional DNA analysis fails.
- It targets rare and aggressive tumors like:
1. DIPG (brainstem tumor)
2. ATRT (rhabdoid tumors)
3. Ependymoma
4. Infantile fibrosarcoma
5.Pediatric kidney and CNS tumors
🧪 Who’s Behind It?
- Invented by top scientists including Dr. Linda Liau, now NWBO’s Chief Scientific Officer.
- Co-owned by University of California and Children’s Hospital of Philadelphia (CHOP)—a strong signal that it’s aimed at pediatric use.
🚀 What’s Next for NWBO?
- NWBO could integrate IRIS with its existing platforms (Eden, Flaskworks).
- This means NWBO may soon offer AI-personalized cancer vaccines for children—without needing chemo, radiation, or surgery.
Market Data 
Markets 
AI
